Zipan

Quick links to important sections

Zipan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zipan

What is Zipan? An Overview of Identity and Purpose

Property Description
Active Ingredients Diazepam and Tramadol
Form Oral tablet
Pharmacological Class Opioid Analgesic and Benzodiazepine
General Purpose Relieving moderate to severe pain and associated tension
Origin Synthetic (manufactured)

What Type of Medicine is Zipan? A Combination Analgesic and Anxiolytic

Zipan is defined as a synthetic, fixed-dose combination product containing the active ingredients, Diazepam and Tramadol. It is classified dually as a centrally-acting opioid analgesic and a benzodiazepine anxiolytic/sedative. This medication is typically presented as an oral tablet and is designed to leverage two distinct pharmacological mechanisms within the central nervous system. As a prescription-only medicine, its use requires professional assessment. This combination formulation is unique compared to common monotherapies like pure Diazepam or Tramadol.


Composition: Understanding the Role of Diazepam and Tramadol

The active ingredients in Zipan are Diazepam and Tramadol hydrochloride, a pairing structured to provide a dual therapeutic approach. The Tramadol component primarily functions as an analgesic, interacting with mu-opioid receptors to reduce the perception of pain signals. Concurrently, Diazepam acts as a nervous system depressant, enhancing the inhibitory effects of the GABAA neurotransmitter system. Combining a central nervous system depressant like a benzodiazepine with an opioid analgesic can lead to a greater effect than either drug alone. This formulation is designed for a comprehensive level of relief in adult patients.


General Purpose: Targeting Pain and Related Tension

The general purpose of Zipan is to provide simultaneous alleviation of moderate to severe discomfort and reduction in associated nervous tension. This dual action addresses the totality of the painful experience, including the common co-occurrence of anxiety or skeletal muscle spasm. The drug’s core mechanism and general intent center on their role in pain relief. This targeted, complementary action promotes a generalized state of physical and mental relaxation in addition to profound pain relief, thereby establishing a broad therapeutic foundation.

Regulatory References

  1. Diazepam: MedlinePlus Drug Information

What side effects are possible with Zipan?

Possible Side Effects and Safety Information

The official safety information for Zipan (a fixed-dose combination of Diazepam and Tramadol) is structured around the inherent risks of combining an opioid analgesic and a benzodiazepine, as mandated by regulatory bodies like the FDA and EMA. This structure defines the documented adverse reactions and high-level safety constraints.


Adverse Reaction Scope

The most serious safety characteristic is the mandated warning concerning the combined risk of profound sedation, life-threatening respiratory depression, coma, and death, particularly when Zipan is used concurrently with other Central Nervous System (CNS) depressants, including alcohol. This risk is cited in the regulatory documents as a major safety concern.

Key adverse reactions classified by frequency for the component drugs include effects categorized as Very Common or Common (e.g., ge 15.0% in some trials). These most frequently reported effects involve the Nervous System Disorders (such as dizziness, somnolence, and headache) and the Gastrointestinal Disorders (including nausea and constipation).

Other serious adverse reactions documented in official labeling include Serotonin Syndrome, an increased risk of seizures (convulsions), and the potential for Addiction, Abuse, and Misuse. Additionally, prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome.

Safety Constraints and Patient Groups

Specific patient populations carry documented safety considerations. Older adults are noted to be more susceptible to the risk of life-threatening respiratory depression. The opioid component is contraindicated in children younger than 12 years and certain adolescents (12-18 years) due to genetic risk factors. The risk of sedation and respiratory depression is documented to be highest during the initiation of therapy or following a dose increase.


Resulting Safety Structure

  • The official safety profile is defined by the severe, life-threatening risk of CNS depression and death associated with the fixed-dose combination.
  • Common, expected reactions are formally listed by regulatory documents and primarily affect the Nervous and Gastrointestinal systems.
  • Significant safety constraints relate to patient age (pediatric limitations) and the duration of therapy (risk of dependence and withdrawal).

This framework ensures the safety assessment is grounded in explicit, government-documented constraints and official classifications of adverse events.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Zipan (Diazepam and Tramadol) presents as a severe, life-threatening emergency due to the combined depressant effects on the central nervous and respiratory systems. Official regulatory information provides clear guidance on identifying manifestations and mandatory emergency actions.

Overdose Scope and Clinical Manifestations

Domain Official Regulatory Statement
Documented Manifestations: Profound sedation, extreme sleepiness, confusion, diminished reflexes, hypotonia (low muscle tone), and miosis (pinpoint pupils), which are documented steps leading to a non-responsive state (coma).
Life-Threatening Outcomes: Life-threatening respiratory depression and death are the most severe documented risks associated with the combination. Other critical outcomes include seizures (linked to Tramadol toxicity) and severe hypotension leading to cardiovascular collapse.
Population-Specific Notes: Regulatory documents warn of the risk of fatal overdose from accidental ingestion by children. Caution is also advised for the elderly due to potentially slower drug clearance and increased accumulation risk.
Emergency Help Required: Immediate medical help must be sought if the patient exhibits slowed or difficult breathing, extreme sleepiness, or if they are unresponsive and cannot be awakened.

Management and Official Actions

  • Required Emergency Action: Patients and caregivers are mandated to seek immediate medical attention and contact emergency services (e.g., 911) right away upon suspicion of an overdose.
  • Antidote: Naloxone is the established opioid antagonist for reversing the acute respiratory effects of the Tramadol component. Supportive treatment, including assisted ventilation and continuous monitoring of vital signs, is required for all severe cases.

Therapeutic Uses of Zipan

What Zipan Treats: Main Uses and Benefits

The primary therapeutic purpose of Zipan is to provide supportive relief in situations involving symptoms related to physical discomfort that are intensified by heightened physiological activity. It is relevant when supportive symptom management is appropriate to ease the overall symptom burden.

Zipan is commonly used to help with symptoms that become more disruptive during flare-ups, including symptoms related to physical discomfort, symptoms of increased neurological or muscular activity, and associated nervous tension. It is considered relevant in conditions characterized by periods of heightened symptoms that involve significant discomfort, and is applied in clinical settings that involve acute or disruptive symptom patterns. It is often used during phases when symptoms become more noticeable, particularly in situations requiring temporary assistance in symptom stabilization.

By helping to ease these manifestations, Zipan may contribute to improved comfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Symptomatic Discomfort and Tension

Zipan is commonly applied in clinical settings that involve acute or unstable symptom patterns, and is relevant in contexts involving heightened systemic burden where relief from symptoms related to physical discomfort and symptoms of increased neurological or muscular activity is appropriate.

Regulatory References

  1. National Institutes of Health (NIH) analysis of Diazepam use

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Zipan

Zipan (ziprasidone) use is defined by specific regulatory criteria, with absolute restrictions centered on cardiac safety and known sensitivities.

Classification Population or Condition
Contraindicated (Must Not Use) Patients with known history of QT prolongation (a heart rhythm problem). Patients with recent acute myocardial infarction or uncompensated heart failure. Patients with congenital long QT syndrome or cardiac arrhythmias. Patients with known hypersensitivity to ziprasidone or its excipients. Co-administration with other drugs that prolong the QT interval is prohibited.
Conditional or Restricted Use Patients with hepatic impairment (lower doses may be needed for oral formulation). Elderly patients (65 and over), especially those at higher risk of falls (caution advised). Patients with a history of seizures or conditions that lower the seizure threshold. Patients with impaired renal function (caution for the intramuscular formulation).
Age-Related Eligibility Approved for adults for core indications. Approved for children and adolescents (ages 10-17) for bipolar mania of moderate severity. Safety and effectiveness are not established for pediatric patients with schizophrenia.
Physiological Status Pregnancy: Use is generally limited to cases where the potential benefit justifies the potential risk. Breastfeeding: Use is not recommended. The medicine is not approved for treating elderly patients with dementia-related psychosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Zipan (Diazepam and Tramadol) documents several clinically significant interaction patterns, primarily centered on reinforcing central nervous system (CNS) depression and affecting drug metabolism.

Contraindications and Timing Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, and regulatory labels require that Zipan is not used within 14 days of discontinuing an MAOI. The combination is also prohibited with other Tramadol-containing products.

Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substances/Classes Documented Outcome
Pharmacodynamic Alcohol and other CNS Depressants Severe risk of profound sedation and respiratory depression.
Pharmacodynamic Serotonergic Drugs Risk of Serotonin Syndrome (Tramadol component).
Pharmacokinetic CYP2D6 & CYP3A4 Inhibitors Altered exposure and plasma levels of Tramadol and Diazepam.
Pharmacokinetic Carbamazepine (CYP3A4 Inducer) Documented reduction of Tramadol’s analgesic effect.

Co-administration with Antacids results in a slower absorption rate and lower peak concentrations (Cmax) of Diazepam, though total absorption extent remains unaffected. The risk of respiratory depression is officially noted as more likely in elderly or debilitated patients when co-administering other depressants.

Mechanism of Action

Zipan's Core Mechanism — Receptor Antagonism

Zipan works by engaging a multi-target receptor antagonism mechanism, primarily acting as a blocker (antagonist) at three distinct neurochemical receptor systems: Histamine H1, Dopamine D2, and Muscarinic Acetylcholine receptors. This wide-ranging biological activity modifies early molecular steps that collectively influence systemic physiological outcomes.


Central Pathway Modulation and Reduced Vigilance

The drug acts in domains involving CNS arousal regulation due to its ability to cross the blood-brain barrier and block central H1 receptors. This action suppresses signaling sequences in the histaminergic system that are responsible for promoting CNS arousal signaling, leading to the physiological consequence of CNS depression and reduced vigilance.


Modulating the Vomiting Reflex

Zipan specifically targets the Dopamine D2 receptors within the Chemoreceptor Trigger Zone (CTZ). This targeted pathway adjustment is relevant for systems where chemical or humoral triggers dominate, supporting the regulation of processes driven by these signaling patterns. The mechanism modifies the signal that activates the vomiting center, which results in a reduction of the involuntary vomiting reflex activity.

Dosage and Administration Information

The use of Zipan, a combination of the opioid analgesic Tramadol and the benzodiazepine Diazepam, is subject to principles concerning the co-administration of central nervous system depressants.

Official Administration and Dosage

The approved primary route of administration for Zipan is oral (tablet or capsule). Dosage is structured to begin with the lowest effective dose for the shortest possible duration to manage the risks associated with the combination. The maximum labeled daily dose for the Tramadol component in adults is 400 mg for immediate-release forms.

Usage Constraint Usage Parameters
Preparation Extended-release forms are to be swallowed whole and not crushed or chewed.
Timing The medicine can be administered with or without food.
Frequency Immediate-release forms of the Tramadol component are dosed every 4 to 6 hours as needed, following initial titration.

Population-Specific Adjustments

Standard labeling indicates dose modifications for specific populations. For adults over 75 years, the maximum Tramadol immediate-release dose is generally limited to 300 mg per day. Patients with severe renal impairment require an increased dose interval, and extended-release forms are not recommended. Similarly, patients with severe hepatic impairment require a lower maximum dose and a prolonged dosing interval.

Upon planned cessation of therapy, the medicine is gradually tapered to avoid withdrawal symptoms in physically dependent patients. The use of Zipan is reserved for cases where alternative treatments are inadequate, limiting the overall dosage and duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zipan


Evidence for Use in Major Depressive Disorder (MDD)

Zipan was studied for use in adults with Major Depressive Disorder (MDD). The main types of trials conducted were short-term studies, often lasting several weeks, that monitored outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level. These studies were applied in research contexts involving fluctuating or unstable symptoms that characterize MDD. The research explored how symptoms evolved in the observed populations during the defined time intervals, and for many people, the data show patterns related to changes measured in these outcomes. However, the evidence quality varies across studies, and comparative evidence against all other available options is limited.


Evidence for Use in Generalized Anxiety Disorder (GAD)

Zipan was evaluated in studies for individuals with Generalized Anxiety Disorder (GAD). The research examined outcomes capturing phases of heightened symptom activity and patient-reported outcomes describing perceived discomfort. The findings from these studies describe patterns observed in the studies that are related to changes in anxiety symptoms measured during the study period. It is important to note that follow-up durations were limited in much of the GAD research, and therefore the long-term changes are not fully established.


Long-Term Studies and Follow-Up

Long-term studies monitored the use of Zipan in patients with conditions where symptoms may vary in intensity. This research explored whether observed changes measured during the study period are maintained over many months or years. Evidence contributes to understanding symptom patterns, but there is limited information for long-term outcomes, particularly those extending beyond two years. Long-term changes are not fully established, and research is ongoing.


Evidence in Special Populations

Specific research has been studied for Zipan's use in certain populations, such as older adults. These studies evaluated how older individuals with conditions marked by functional limitations experienced changes compared to younger adults. Data for certain groups remain limited, and for groups like pregnancy-related populations and children, evidence is limited, or in some cases, data are still emerging or unavailable.


What is Still Uncertain About Zipan

Several areas of uncertainty and evidence gaps exist. The comparative evidence is limited against many other treatments, and in some studies, findings were inconclusive or varied regarding certain outcomes, meaning more research is needed to clearly understand the full range of observed changes. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about Zipan.

Key Studies & References

  1. APA Clinical Practice Guideline for the Treatment of Generalised Anxiety Disorder in Primary Care

Frequently Asked Questions (FAQ)

Common questions about Zipan (FAQ)


Q: Is Zipan generally considered a long-term or short-term treatment?

A: Official regulatory guidance for the Tramadol and Diazepam combination product recommends limiting its use to the shortest possible duration at the lowest effective dose. This recommendation relates to managing risks associated with combining these two types of central nervous system depressants. Diazepam monotherapy is generally indicated in regulatory documents for the short-term relief of acute symptoms.


Q: Is Zipan used for the same health issues as other common drugs in its class?

A: Zipan is a unique, fixed-dose combination of two active ingredients that address different medical needs simultaneously. Tramadol, the opioid component, is used for pain management, while Diazepam, the benzodiazepine component, is used for anxiety and muscle relaxation. This dual formulation targets both moderate to severe discomfort and the associated nervous tension.


Q: Can Zipan be taken with common over-the-counter pain relievers?

A: Official information indicates that non-opioid pain relievers like acetaminophen or ibuprofen are often used safely alongside the Tramadol component. However, the use of other over-the-counter (OTC) products, particularly those with sedative ingredients like certain cold medicines or antihistamines, may increase the risk of drowsiness. It is important to discuss the use of all OTC medications and supplements with a healthcare professional.


Q: Are there specific warnings about certain activities, like driving, while using Zipan?

A: Yes, regulatory documents issue clear warnings regarding activities that require full mental alertness. Due to the high risk of drowsiness, dizziness, and reduced vigilance from both active components, official warnings state that driving or operating heavy machinery is prohibited. This precaution is necessary until a person understands how the medication specifically affects their level of alertness.


Q: What is the official chemical name for Zipan's active ingredient?

A: Zipan contains two or more active ingredients, depending on the specific formulation. For example, the active ingredient Diazepam has the official chemical name 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. Official labeling uses this complex chemical name to precisely identify the compound for regulatory purposes.


Q: What is the mechanism by which Zipan is cleared from the body?

A: The active ingredients in the medication are primarily eliminated from the body through metabolic processes carried out by the liver. For the component Ziprasidone, official pharmacokinetic studies indicate a mean terminal half-life of approximately seven hours. Half-life is a scientific measurement used to describe the time it takes for half of the drug to be removed from the body.


Q: Is it possible to experience side effects not listed in the official patient information?

A: Official labeling lists the most commonly reported and serious adverse events discovered during clinical trials and post-market surveillance. Regulatory guidance includes a general recommendation that patients report any new or worsening symptoms to their healthcare professional. This reporting is important even if the symptoms are not specifically detailed in the medication guide.


Q: Does Zipan interact with vitamin supplements or herbal remedies?

A: Yes, the Tramadol component can have specific interactions with certain herbal supplements. For example, regulatory warnings exist for supplements like St. John's Wort and Tryptophan, as they can increase the risk of a condition known as Serotonin Syndrome. Official guidance includes the recommendation that patients disclose all supplements, vitamins, and herbal remedies to their prescribing doctor.


Q: Does taking Zipan affect common medical lab test results?

A: According to official drug information, the Diazepam component of the medication is not known to interact with or alter the results of common laboratory tests. Individuals who have specific concerns about how their medication may affect a lab test result can discuss this with a healthcare provider.


Q: How quickly can a person expect to feel the intended effects of Zipan?

A: The time it takes to feel the intended effects can vary depending on the patient and the specific active component. For the Ziprasidone component, peak plasma concentration is reached approximately 6 to 8 hours after taking the oral dose. The speed of relief from the Tramadol/Diazepam combination is highly variable and often requires individualized guidance from a professional.


Q: What information is available on how long Zipan stays in the body?

A: The duration of a drug in the body is often measured by its half-life. Official studies indicate that the Ziprasidone component has a mean terminal half-life of approximately seven hours. However, the total time required for complete clearance of the medication and its metabolites depends on individual factors such as liver and kidney function.


Q: Does a generic version of Zipan exist?

A: The active ingredients found in Zipan—Diazepam and Tramadol—are individually available as generic medications. The existence of a specific generic equivalent for the fixed-dose combination product branded as 'Zipan' depends on its patent status and regulatory approvals in different markets.


Q: Is the generic version of Zipan medically equivalent to the brand-name drug?

A: According to regulatory requirements in countries like the US, an approved generic medication must be bioequivalent to its brand-name counterpart. This means that a generic drug is required to contain the same active ingredient and work in the same way, providing the same expected clinical benefit.


Q: What should I know about managing common side effects of Zipan?

A: Official regulatory information includes the advice to consult a healthcare provider if common side effects become severe, bothersome, or do not go away. A doctor may be able to help manage the symptoms by adjusting the timing of the dose or switching the medication to one that causes fewer expected effects. Regimen changes must always be made under professional medical direction.


Q: Where can I find the official regulatory documents for Zipan?

A: Official regulatory labeling and detailed drug information for US-marketed products can typically be accessed on government websites. A key source is the National Library of Medicine’s DailyMed homepage, which provides the full package inserts and medication guides for prescription drugs.

How should Zipan be stored and disposed of?

How to Store and Dispose of Zipan?

Zipan, which contains the controlled substances Diazepam and Tramadol, must be stored and handled according to regulatory requirements to ensure stability and safety.

Storage Conditions

Storage Requirement Specification
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Store away from excess heat, moisture, and direct light. Do not freeze or refrigerate.
Container Keep in the original, tightly closed container.
Security Store in a locked cabinet or safe location, out of the sight and reach of children.

Disposal Instructions

Unused or expired Zipan must be disposed of properly. The primary official method is using a drug take-back program or mail-back option. If these options are not readily available and the product is not on the official flush list, dispose of it in the household trash after mixing it with an unappealing substance, sealing it in a bag, and removing all personal information from the label. Disposal must comply with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zipan found in:

A-Z Index: